MRSN - Earnings call transcript Q2 2024 | Mersana Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to Mersana Therapeutics Second Quarter 2024 Conference Call and Webcast. [Operator Instructions] Please note this call is being recorded.

I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications.

Jason Fredette

Thank you, operator, and good morning, everyone.

Before we begin, please note that this call will contain forward-looking statements within the meaning of federal securities laws. and but product limited trial candidates, data, development include, to those execution may business platforms, our business efforts statements are to, not related and These runway. cash strategy, clinical could such forward-looking these materially to uncertainties to are . Each cause projected of results in statements actual those risks subject and that statements. from differ filings. Commission on in with the filed These uncertainties discussed are XX-Q and risks XXXX, in and Form on Exchange and subsequent X, SEC our quarterly report May Securities

available and sec.gov website, are our filings Our at mersana.com. on

as update DeSchuytner. Operating required Executive Chief the have if and Officer that, becomes by obligation Except we our With law, we begin Officer, me turn Chief let and in forward-looking new over Officer, Chief no Financial assume the Dr. available future. to call, President call even discussion. On Martin today's statements Huber to to Brian publicly Mersana's our information Marty and

Martin Huber

good Thank you, and morning, Jason, everyone.

of was efforts of progress second reduce in XMT-XXXX, The trials candidate. progress and our of Dolasynthen dose as our clinical while time, we collaborations last XMT-XXXX, benefiting continued Mersana also lead at same expenses Immunosynthen made ADC we XXXX in I At ADC our lead advanced year. our further candidate quarter escalation Phase our from the the operating time to

half our second these believe the data clinical initial readout approach this strong collective planned for we for We accomplishments which as have a put year. in position XMT-XXXX, is us of

can and as within prognostic the for cytotoxic types. Let's cell protein BX-HX, platform. family multiple targets begin negative developed that This a ADC we using Dolasynthen, with program. ADC a suppress our can next-generation an that indicator XMT-XXXX immunity is surface tumor serve antitumor BX candidate

recurrent escalation cancers, and as that medical positive commonly with high I all portion our These In and types as unmet high enrolling are trial, clinical endometrial hormone ovarian patients well the need. with include breast express levels patients most cancers with triple-negative BX-HX. receptor tumor Phase of we ongoing areas dose of

used For know, cancer the Topo instance, Emerging many vast majority to as can Trodelvy with patients payloads. being X that recurrent clinical U.S. data breast inhibitor suggest in of in resistance the ADCs develop today. HERX to treat are to continue patients and/or triple-negative

we in As resistance tolerated call profile. ADCs And enrolling we patients still this our aren't Dose prior with for who result, are fits are remains and have PGP hearing escalation a dose. treating mechanisms. or subject received ADC Topo maximum have physicians XMT-XXXX ePlex increasing payloads among Topo an alternative X a established many a new to we ongoing, X trial. not that

In escalation. fact, at the of squared prior milligrams able dose to in dose we we This meter is ADCs. with a are per levels our were XX of reach clinically well beyond any currently

X continue to ability to attributed our We escalate to believe can dose factors. be

to dose The aim Dolasynthen's to are our with with exploring different proactively which that appear liability and as also second to neuropathy cohorts, neutropenia, of be toxicities been and associated with first platform, not an does schedules on-target BX-HX. with In we parallel, optimize there backfill escalation date our obvious XMT-XXXX dosing with enrollment safety. efficacy the the includes work, the to ocular well seeing that ability ADC based commonly reported like factor has as data that is we're reduce those And on platforms is with Dolaflexin. toxicity first-generation other

can that later in This development. combination best-in-class may this position as serve stages be as our time, the same monotherapy At we frequent asset, progressing dosing for of a has opportunity XMT-XXXX set a as well both are decisions to that of strategic to other care is robust aimed BX-HX important have development. ADCs preparation we one for expansion the in inform as inaccessible and believe and regimens. potential every more at potential we seek All X strategy also in as data work included building with the biomarker weeks they a standards that

We announce initial half initiate the readout and tolerability, a of data to continue this year. our that will expansion efficacy biomarker in we data. position clinical include be to in This and will safety, second expect

STING tumor-resident both in This Now efficacy serum in in mechanistic free XMT-XXXX. demonstrating let's the were comparison using turn showed and cells. communications data ADC. targeted consisting underpinnings agonist. elevations STING an our stimulating STING cells ADC antitumor immune Nature cytokine The is in a of of to preclinical and publish immune month, data included Immunosynthen and an key also manner to Last reduced in some punch pleased Immunosynthen we approach to tumor in innate platform. vivo to regarding vitro increased activate a target-dependent activation a X-X of and data

a be candidate XMT-XXXX is novel to a could an could but monotherapy, agonist targets that It advancing with is with cell HERX believe The patients including eventual allow trial agents, other our colorectal combinations using lead tumors, dose immunosynthen. we and Phase enrolling only enable it other is STING HERX-positive non-small and ADC that lung effective cancer. for portion developed of escalation range gastric, our also I HERX-targeted including we therapies. of not epitope breast,

escalation year. in progress good make to this expect We

to that & our And Johnson we collaborations report I'm Johnson advance discovery finally, KGaA. and pleased Merck to with continue

month, milestone third CMC performing this $X of have this is earlier support we to milestone, for collaboration. Payment fact, related Dolasynthen of activities XXXX. the And that in been earned another we one to million quarter J&J. due In this

Now over update. Brian things financial QX let's turn for to our

Brian DeSchuytner

Thank you, Marty.

starting quarter second $XXX.X equivalents and Let's cash, quarter cash in sheet. XXXX, get million with our marketable ended securities. We with balance second the into highlights the financial the for of

into guidance funds any realize from XXXX. our that we support our operating that proceeds that cash available Please assume commitments payments from We plan to will current milestone continue future collaborations. may collaborations not expect our we runway earn note our or future does may

second cash the XXXX down $XX.X in of decrease used primarily the half from This efforts reductions second for the reflects the during OpEx the and quarter. of quarter year million, ago net used in XXXX. was significantly cash portfolio we reprioritization Net in million operating activities implemented $XX.X

income quarter of collaboration our million XXXX. recognized agreements. reduced for in compared period Turning to Johnson was XXXX statement. to The same primarily $X.X million KGaA change year-over-year for related our Johnson Collaboration the collaboration to the under $XX.X revenue Merck revenue was second and &

development expenses same and XXXX Research significantly $XX.X of declined the million for compared second to in for the $XX XXXX. quarter million period to

related approximately for reduced with this $X.X the manufacturing compensation For and and year-over-year employee [indiscernible] reduced XXXX. costs to stock-based recent related in primarily completed discontinued following quarter, compensation. ADC restructuring decline expense we of spending was was noncash million R&D to associated expenses activities our the clinical in The most

compared most decline second General and our to related G&A for significantly in administrative the primarily G&A recent and period in $X reduced $XX.X the restructuring. expenses reduced of quarter. million same was XXXX, to included and the for during The million in professional consulting compensation expenses to approximately $XX.X XXXX million fees compensation in declined noncash expenses, quarter following services year-over-year were employee stock-based

same million to XXXX concludes for net business And $XX.X That finally, loss of Mersana's of compared loss second was a the update. our in XXXX. period $XX.X million net for the quarter

call the for you please would open questions the Operator, audience. from

Operator

with Cowen. from Tara question comes Bancroft Instructions] [Operator The TD today first

Tara Bancroft

events doing So MTD that observed, you you trial. or other responses you're previously patients give And the qualitative in of grade reached, are have level X hoping I then? the that deepening happy you observed but noted could you than was us a are being maybe since for measure I no mean are safety, more of with how being seeing?

Brian DeSchuytner

Thank you, Tara.

a While of per we're equates is X.X XXXX which we couple giving are than clinical milligrams are points the there previously square. is, much one, not kilogram, higher at is milligrams details meter XX And I this to we've the any gone think platform. per on dose that roughly on a data,

we So et of while range. comfortable escalate we're about X, to dose not able events, to details Grade this that are we're talking cetera

We're not responses included information time. be any the second details getting half into will our in disclosure. this data in That at point on

Operator

The with Partners. from next comes Chang question Jonathan Leerink

Jonathan Chang

biomarker second any and granularity you when disclose clinical you're much data? initial First the can plan XXXX see XXXX. what disclosure? provide the on and could question, data progress how more to and biomarker the in on second the half front you question Can how And we you on making discuss

Brian DeSchuytner

going answer, to and I'm to going future With disclosure. that expression just cover all turn with triple-negative the that ovarian levels receptor-positive of regarding and cancer, Jason biomarker then BX-HX. endometrial remind the breast regards to I'm everybody, the types, have to breast to patient it hormone biomarker, of populations over cancer, higher tumor selected we

requiring be we populations, those be to within positive However, are a biomarker patient enrolled. to not

all comers across enrolling we're words, other In that.

of are are analyzing We tissue, BX-HX. retrospectively expression capturing we the which for

information necessary some patient what is in on believe the of So us do you with plan that we'll allow thinking disclosure for going provide be share -- not. initial kind biomarker a to would data or will be forward our we would selection our

of not that biomarker negative to we continue and gather As data we'll inform today, on decision, have decision. positive but that to made

Jason Fredette

additional the a And event at share at We're We stage. could at stage, company have medical it really that. Jonathan or this guidance be that congress don't if . color haven't to color. on be half, additional keeping this second could we defined a

Jonathan Chang

more Also If maybe X I XXXX. just here. could it. question on in Got fill follow-up

of need in guess, you what address initiating study? committed see have already expansion I to portion this before portion study. the clarify, to expansion the Just of you the do to

Brian DeSchuytner

We the the protocol. expansion have built cohorts existing into

the work So defined not recommended forward a we II recommended point dose an into at have all in that Phase been this identification not is has to least time. recommended of the a at yet phase yet ready Phase declare dose we're to as II The to step left we X take And expansion. done. MTD, are

Operator

with Mubarack The next Citi. from comes question Ashiq

Ashiq Mubarack

we've your you've In I'm are how to X seems you the the any sort color in weeks, in potential through in could differentiator. some a are share think of point, to close frequency talked that dosing how need process from and wondering you dose which mg optimization. every if be And exposure? dosing curious you out the past, where compared of called space. work the you frequent I BX-HX release, I'm could seen out as a on about think optimal you less just the on data similar important to the figuring press exposure the with be peers XX

Martin Huber

the for you question. Thank

and our we able about shared have -- have X to shows molecule every spoken molecules. X-week we're the an schedule all, is First and to compared explore weeks, the of the we preclinical every half-life data X of we extended reasons other because

have ADCs. antibody-like half-life our We for Dolasynthen

to That we maintain relative that more at more advantage longer more the don't time. time, an it decision same we in and be of decrease frequent to the you answer have we more the explore in to schedules dose for. dose the question half-life AUC long to got every unknown exposure the may which that to a frequent one But over allows do be we -- dosing is the proactively think have X-week to when escalation you Cmax -- made have schedule could explore reasons So schedules. that's an potential these frequent clinic. parallel more effective And

are data to have that II but as we define of of on that both also So X only half dose, and second is, as shorter dose every well schedule. Phase the with week part should recommended allow which us, the generating as would intervals, as then appropriate part presentation, not data the we

Ashiq Mubarack

Okay.

it. one I could And follow-up. ask Got Okay.

before to Is the establish . dose point necessary? I necessary the is with data? think you've needing as to study you Phase a the an per alluded MTD maybe also the establish us. before Or of not that II in end primary to the it sharing show past data

Martin Huber

necessarily critical. an to don't not have get is MTD We MTD. to

we can want you think bound a I to Phase of though, get whether specified upper of declare to dose, you're of -- kind some just effects. general is have where that's to, understanding a see recommended II payload formal we protocol the to before is observation a or MTD that starting

fact the have we saying we want MTD. to indices. see ADCs So be had careful to think an little we I -- I But that have therapeutic given historically narrow relatively a think

to do is where expansion. think kind to want see we which we we're make a upper call I that bound of on before dose taking

Operator

Schmidt Michael from comes question next Guggenheim. with The

Michael Schmidt

every if in dose I I comment you've could know bit seeing a cohort responses the commented more XX far. dose. dosing on wondering than whether the weeks milligram you earlier observed a was you response so have X on

then expect And those increase curious. just perhaps would in So schedule? magnitude a of also, one with frequent more what dosing exposure

Brian DeSchuytner

Michael. relationships. We're exposure Thank not further you, color sharing any on response

before previously that to at [indiscernible]. doses I think we we had did we responses disclose got

can that we in doses point that be lower will And that responses half was XX our -- data response relationships explicit think we than disclosure. to previous I be the . So exposure we disclosure. and be in at second premature at the what of that this with regards have and seen time, would lower part

was. second of The part your question

Michael Schmidt

I I [indiscernible]. data was it on some I'm think question that. for as pursuing from other will who had -- companies forthcoming other how curious AstraZeneca, is [indiscernible]. there yes, we the monitor just have BX-HX, And example,

Jason Fredette

and coming some speculation you're . Michael, you Yes, in Are asking for about out. AZ?

Michael Schmidt

I'm Yes, we on if reprove how that? look interpret of as there should you just their forward have [indiscernible] investors and they update it [indiscernible] data, kind curious how your to may an program,

Brian DeSchuytner

like include we expect I maybe tolerability to Sure, typical see would From safety things and Those X Michael, that. can perspective, the Topo toxicity. handle myelosuppression. platform a

which less the From efficacy question be many combination generated for standpoint, shows where how AZ may of ADCs. its space that in asset including be extent locations an more have trial think potentially to been cancer, are this to the X that's X opportunities we to been frankly patients who with breast those challenging like likely the previously Topo has it be naive relevant that. speaks or globally, prior will responses responses in to I . [indiscernible] enrolling believe in ADCs. patients more because treated in an Topo were

can about cancer Here in resistance recurrent ADCs suggest Topo with triple-negative we've to the treated vast in are with this payloads. the majority Emerging that before, to and/or patients X of develop being data, and U.S., continue those break spoken HERX. TRODELVY patients

in Topo subject resistance call from with aren't pump. the ADCs a remarks, or result, noted to physicians sort to of mechanisms as an opening Marty payloads As there's increasing find PGP new that the fatal

treatments those I is should prior of that patients. question the those demographics So what for be guess the looking are people key and

Operator

[indiscernible] [Operator with Instructions] from LifeSci. The next question comes

Unknown Analyst

have that towards as pretty relevant doses protocol backfilling, thinking at dose-escalation/exporation been this thinking XMT-XXXX clinically to prioritizing and has more your collecting advance for into evolved or Given about cohort. backfill allows how further schedules. given enrollment are continued advancing data sizable versus any you thinking further And you've

Martin Huber

the to dose everybody, just XX as Well, given up you to at first of all, given yes, well remind allows patients at for as indication. protocol, a a

at type. probably medical a been lot I the do spend we the think patient So area given that does flexibility a us think it give explicit dose of and tumor one to that? probably fairly highest significant get time need. is the we How unmet numbers talking about it's TNBC we've most about as of

frequent from what So how TNBC in we're data differentiation . It's I is look is do would toward medical fairly area, high in need, think getting an unmet second to Brian this to as the -- we patients, there. alluded the a BX-HX others. one, set is

linker its be topo a an a where unlikely will ADC HERX opportunity in payloads at that novel to show Trodelvy Looking most hypothesis population to explore scaffold the patients activity our are is U.S.-based with settings and/or will to effective. payload in TNBC great where have seen have place

-- giving designed, that details of So I way for not the or tumor we with activity answer backfills us, this post and that enroll the while of what protocol what's try of [indiscernible]. expand the patient exactly types, think TNBC can we're kind other of question is types really to the

points data the in of be should disclosure. that to sets the able should but So one our -- we would that of second one include data half we be

Unknown Analyst

maybe And could ask follow-up on one it. I just that. Got if

that to what or project sounds you guess assume end backfilled at FDA made optimist than your one across year? environment each dose opposed fair by given go-forward patients more to would is I to given backfilled as intention on level to then it determination enough of take the then, have dose like and that Just have this

Unknown Executive

in rolling expansion -- of we're We to things least at be want in the The It answering Phase from Optimus here questions dose. of gives we X. could in of is One Project some one the with if flexibility I that way the take II for recognize multiple go having or be written is agency, need it the do us patients [indiscernible] way and time, out, X to study the careful will look X we But likely protocol, the doses point careful. X. the at the backfill guidance at meaningful have formally at you precedent doses. formally some will to project Optimis. does direction and recommended

we would to the the So number take into minimize doses of actual hopefully, programs. will pivotal have it

are is doses into And on I registration X programs. there registration-enabling to we or there mean, or out schedules opportunity precedent X folks there targeted and who based today large narrow are taking an down. going at pivotal the to agency. the to multiple more potentially. X out backfills better we'll doses, we discussion But have study inform the Are get the these that of we in information doses with think

Operator

Colleen comes The . from question with next Kusy Baird.

Colleen Hanley

And cohorts readout, the in expansion set tumor escalation will open data an biomarker meaningful second looking multiple can On half of that to we or subgroup. upcoming from would determine year, expansion for all you enrolled cohorts. open patients enough this to data And be to expect backfill? that the plan XXXX specific that one positive you then the ORR in biomarker in be

Brian DeSchuytner

you to a don't I the the that one samples be have will the you retrospective biomarker. analysis mean, they of challenges roll the positive before biomarker, will a require to have for regards is With of invaluable patient since documented

not mean to on that thing of going full a what here But remember, -- the So sit and say, and data we're is are it topic. we -- second would I backfills. XXX% -- the be just have This these expansion. to

they any going to be the data as set are seen relatively last this year confidence as [indiscernible] the that way, estimate. applies intervals by point wide. And the [indiscernible] well to presented your around So

to would definitive So have trying out determination response escalation a we I be dose overreaching. of say rate a Phase

sufficient a is, two, biomarker We answer However, differentiation based in there carry some I should may do universe how and/or to have is data studies out negative. the of for expansion do matter, evolving data. directional the all think versus need pivotal greater these And on we there. [indiscernible] that get positive patients look in to into data still

XXX we experience, less were One a a the you back signal, the be out clear There I signal cancer you we lung learned patients, able select to of clear have that careful. than KEYTRUDA don't a on want to subset. things really if had quite after

to when the there didn't think I we pivotal a that, perform go back ultimately, the experience, had to [indiscernible] data. our consequence -- our the on well. biomarker so on study ability And negative

really it based the performance not I drug think is the how data-driven performs, I of performance of on So a biomarker, a the the decision the mean itself. also biology the only but biomarker then -- specific

on So that want questions a data. of there based to are lot answer we

Colleen Hanley

That's just multiple expansion or helpful. cohorts, And second one half. Great. in then the open would if the on you

Brian DeSchuytner

in We X at have the all X written protocol. written -- least into

we'll ones do decision point either that which data-driven Phase data some I. decisions can however, in and be -- a . at prioritize time. or flexibly make on that We probably we them on based based the the from will or However, stage more,

Operator

question JPMorgan. next from Brian with comes The Cheng

Unknown Analyst

comments then earlier to perhaps is the your secondly, by MTD expansion? that of satisfy that driven in to And to project dosing, you want frequent on to Just Or development to by up dose the any some your is ongoing observation the [indiscernible] a typical requirement related and work optimist? of just plan Phase around to actively -- clinics? more our move II need into part then reach recommended declare follow do

Brian DeSchuytner

late say before thing we question define ADCs Phase on actually like we when is what a With world, up the that get dose to for a we first lower II to And patients MTD, you this and especially we'd regards in think but is specified level what X these in perfect pick in that of highlight a recommended end a dose. the couple I we formal would situation where MTD formal can stay protocol MTD, on then a have your [indiscernible] project program, know to of want that see sometimes The on, you taken more you achieve aren't toxicities a to able than to dose. don't cycles.

want to want see of part treatment stay vast to be to cycle. do can protocol. patients on II it majority a does say we which to recommended We MTD that I understand has throughout toxicity their may want be formal make But to dose is become of So sure per it Phase tolerable, the not That's limiting. we dose where clarify. truly an where means we want dose our opportunity

With regards to your second question the. was

Unknown Analyst

the was What more frequent.

Unknown Executive

and toxicities [indiscernible] a this decision see can look high be Yes. that at We decision at parallel. that tend we saying, doing made ADCs more initial the point, from we data the the explore you that instead to how [indiscernible], by We of if we looked frequent in going data or with with announced X- a -- at sequential, made there's exposure doing the we we go the delay then Cmax in every on related. And certain platform increase that schedule. dosing, could X-week in back to with and observation

AUC be don't for is to So this related dose-limiting if today, platform. toxicity we Cmax know going or

we things into dose the been able the this on remind this molecule people, first is to we've to like platform range. of One that get this

are learning we So how the behaves. platform still

the where As NAPI not we so BX-HX, in you -- on-target initial has shown saw by that's NAPI driven far at ILD the target not And the we look the was for really Xb, toxicity. when XXXX, mediated toxicity. our competitors, mediated recall, dose-limiting molecules, toxicity dose-limiting the just the

doses higher exposures. So us learn in an this for is our to platform really and these about opportunity

Unknown Analyst

it. just may. if follow-up, more one I Got maybe And

interesting that Cmax to profile. you thinking it about Cmax, you sure your you're about the make it's evaluating think have talked the around thoughts how that I and optimal

the your your and Just going to comments understanding your lot optimize to release, on back emphasized current I efforts dosing. how press a frequent think you in

go progress in current close you think date, this or can to you understanding your XXXX with how are So platform? high about you as

Jason Fredette

Yes.

much escalation to hit we'll for we and as Brian, said think, being. that not we've I probably at MTD, still can. . We're it in time have an leave as the dose just have

Operator

[Operator next from Truist. comes question Asthika with Instructions] The Gunawarden

Asthika Goonewardene

expansion you cohorts taking X be running level expansion So be multiple I into than that sense. cohort more that dose with conducting and appreciate you makes in frequencies would might But the parallel.

maybe patients pension a [indiscernible] to able think say, same couple if And pivotal [indiscernible] Would the And So [indiscernible] SS you running make different in XX XX cohorts, the at do in the level. not each to Marty, at I of then, you levels. in do that dose phase be meet need then recruit requirements? same the dose let's requirements maybe a dose have cohort would Or quick not with to cohort project study? that you were follow-up. you to the

Martin Huber

frequent point in have to dose is less a the we're be want so speculate that. that it more take different schedule. versus possible your written to And if that. recommended it question, just dose to I to It's at dose yes, and forward. take you you Phase when is, schedules If recommended regards II is be probably I question first yes, could dose explicit. premature the more answer. want do With to would forward, But for that we the protocol X say flexibility time, on going frequent really do we Phase dose a dose, should how that's we II would this

purely a had we regards now registration-enabling coming studies. -- question, not speculation to specified we have are we're getting as second into forward With with your not

clear form for dose -- So the to I'm randomization I having current generally, to do to what in giving want you some is your most theoretical environment. a be of people point, are

et an we're look talking in the you don't those doing which do today that you we And matter when you will a of I plans, as your space, that your strong at expansion part I think Ultimately, to to go of rule alternative you're about all think our or not out dose. precedents a the registration the therapeutic as of details going somewhere. if pivotal. do randomization frank, of, whether are risk thinking versus on time, of I expansion that benefit justifying the whether some there into And with ADC need data part doing start that our they're all execution, index, be think there. dose efficiency this at of becomes cetera. there's

Unknown Analyst

you're in cohorts? escalation the if seeing the a . a the have -- that then dose Would And going where continue you're also expansion enviable you escalation big situation be approaching of at dosing limiting. couple you're pushed the and it. running that's Got while not signal to dose-limiting you

Martin Huber

continue get scenario. I in -- to and don't to mean into confidence an our option forward, have in dose to we to it's of to to is initiate expansion possible part parallel. escalate recommended for judgment if II MTD If enough that the that got we us. can did we and dose, We and emerges. as the want data as move we've we're say, a get an comfortable we declare be That that Phase

be that made decision not have data. will We based that today, and on

Operator

comes with The next Justin BTIG. from question Zelin

Justin Zelin

Can Topoisomerase of With resistant of activity confidence in your patients? unmet you [indiscernible] patients. differential XXXX talk of experience for the to discussion need

Brian DeSchuytner

can Yes. Maybe I take that.

would our I think that a number to hypotheses maybe subject to lend payload same are mechanism. there themselves think resistance of the might be that not

analyses probably that ADCs as used a been aware, sets, retrospective single ADCs after share Topo of the topoisomerase also and in -- number real-world sites It there sort So in regulation other of topoisomerase resistance have that well that's could might data for PGP have cells to you're might shown to time-to-event a of been be occur. and be substantial related out concentrations come there cancer X, SABCS at are reducing that common enzyme Topo it's just started ESMO, and up places. drug mechanisms a complexes points. really the And out really how to to a last a other in degradation and reinforced ASCO similarity pretty have speak papers this cancer chemical that the which switch resistance mechanism themselves. of don't or data . There pumps end

not topoisomerase, acting a novel And with pump controlled not microtubules. those a not payload is to bystander either not metabolized, substrate. payload, once is DNA, a mechanisms. Our the a It's of PGP or acting on on effect, statin that subject on acting

So we some those you are at differential least activity. theoretically, see would that reasons might think

Operator

like CEO, question-and-answer closing back for This Dr. would over to Huber, session. . concludes remarks. turn our any to the conference Marty I

Martin Huber

in. call, you, of at Conference We'll the operator, and rest dialing York hope in operator. the you the your of you you. Thank New of Wedbush some thanks, enjoy and summer. seeing Thank rest everyone, the for concludes Healthcare This be

Operator

conference has for now The today's you attending presentation. concluded. Thank

may now You disconnect.

Mersana Therapeutics (MRSN) 13 Aug 242024 Q2 Earnings call transcript